Our Mission

Alleviate the symptoms of type 2 diabetes for patients worldwide with a pioneering, reversible implant.

Product Overview
EndoBarrier treatment for diabetes & obesity

Proven Results for Type 2 Diabetes & Obesity

In two separate studies, 80% of patients maintained their achieved weight loss eight months’ post-EndoBarrier removal and 77% maintained it for 12 months or more.

BBC News Video
Endobarrier treatment for diabetes & obesity following 1 year results of ABCD study

Pioneering and Simply Effective.

EndoBarrier is the first Type 2 Diabetes and Obesity treatment of its kind: safe and reversible, with proven benefits and no surgery.

ABCD EndoBarrier Study
1-year results, including 10-year CV Risk assessment – Robert Ryder, MD, 2016

Conquer the World's Biggest Epidemics.
Join Us.

Investor confidence and invigorated leadership are combining to bring EndoBarrier to the US.

BBC News Item
EndoBarrier treatment for Obstructive Sleep Apnoea – 2nd ABCD EndoBarrier study

The Need by the Numbers

The Treatment Gap

Minimally Invasive Procedure Fills the “Treatment Gap”

  • Aids in the treatment of Type 2 Diabetes and Obesity
  • Minimal Risk
  • Cost-Effective

Videos

  • BBC News item

    EndoBarrier treatment for Obstructive Sleep Apnoea – 2nd ABCD EndoBarrier study
  • ABCD EndoBarrier Study

    1-year results, including 10-year CV Risk assessment – Robert Ryder, MD, 2016
  • Product Overview

    Pioneering treatment for diabetes & obesity
  • BBC News Item

    EndoBarrier treatment for diabetes & obesity following 1 year results of ABCD study

GID in the News

5/22

Meta-Analysis Show EndoBarrier Improves Glycemic Control, Induces Weight Loss in Patients with Type 2 Diabetes and Obesity

CHICAGO — 23 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in...
5/18

GI Dynamics Announces Access to 2017 Annual Meeting of Stockholders and Corporate Update

BOSTON and SYDNEY — 18 May 2017 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2017...
5/17

GI Dynamics Announces EndoBarrier CE Mark Suspension

BOSTON and SYDNEY — 18 May 2017 — GI Dynamics®, Inc. (ASX:GID) today announced that it received notification from...
5/7

GI Dynamics Announces Scientific Advisory Board Members to Further Development of EndoBarrier

BOSTON and SYDNEY — 8 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized...